Isatuximab is an IgG1-derived monoclonal antibody that binds to a specific extracellular epitope of CD38.
- TRADE NAME: Sarclisa (Sanofi-Aventis)
- INDICATIONS: Indicated, in combination with pomalidomide and dexamethasone, for the treatment of adult patients with multiple myeloma
- CLASS: Monoclonal antibody
- FDA APPROVAL DATE: 03/02/2020
- CLINICALLY IMPORTANT, POTENTIALLY HAZARDOUS INTERACTIONS WITH:
None known - PREGNANCY: The combination of isatuximab and pomalidomide is contraindicated in pregnant women.
- See adverse reactions attributed to class:
Please login to view the rest of this drug profile.
Page last updated 07/31/2023
